Cynthia M Rohde
Overview
Explore the profile of Cynthia M Rohde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou J, Bowman C, Markiewicz V, Manickam B, Gomme E, Sellers R, et al.
Vaccines (Basel)
. 2025 Jan;
13(1).
PMID: 39852805
: Respiratory syncytial virus (RSV) infections usually cause mild, cold-like symptoms in most people, but are a leading infectious disease causing infant death and hospitalization and can result in increased...
2.
Rohde C, Destexhe E, van der Laan J, Gould S, Coe R, Haenen B
Int J Toxicol
. 2024 Oct;
44(1):3-11.
PMID: 39475677
A BioSafe-sponsored survey investigated how vaccine companies (n = 12) perceive the value of the repeat-dose toxicity studies for safety assessment of vaccine candidates. As all major vaccine developers were...
3.
Hauguel T, Sharma A, Mastrocola E, Lowry S, Maddur M, Hu C, et al.
NPJ Vaccines
. 2024 Oct;
9(1):183.
PMID: 39375384
Seasonal epidemics of influenza viruses are responsible for a significant global public health burden. Vaccination remains the most effective way to prevent infection; however, due to the persistence of antigenic...
4.
Khan N, Sathish J, Rohde C
J Toxicol Sci
. 2024 Mar;
49(3):79-94.
PMID: 38432955
The development and regulatory review of BNT162b2, a COVID-19 vaccine, and Paxlovid (nirmatrelvir tablets/ritonavir tablets), a COVID-19 therapeutic, are benchmarks for accelerated innovation during a global pandemic. Rapid choice of...
5.
Rohde C, Lindemann C, Giovanelli M, Sellers R, Diekmann J, Choudhary S, et al.
Vaccines (Basel)
. 2023 Feb;
11(2).
PMID: 36851293
The emergence of SARS-CoV-2 at the end of 2019 required the swift development of a vaccine to address the pandemic. Nonclinical GLP-compliant studies in Wistar Han rats were initiated to...
6.
Bebenek I, Bannister R, Dubinion J, Fortin M, Liu M, Motter A, et al.
Toxicol Sci
. 2021 Nov;
185(2):119-127.
PMID: 34735018
COVID-19 (Coronavirus Disease 2019), the disease caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) is an ongoing global public health emergency. As understanding of the health effects of COVID-19 has...
7.
Bowman C, Bouressam M, Campion S, Cappon G, Catlin N, Cutler M, et al.
Reprod Toxicol
. 2021 May;
103:28-35.
PMID: 34058573
BNT162b2 is a vaccine developed to prevent coronavirus disease 2019 (COVID-19). BNT162b2 is a lipid nanoparticle formulated nucleoside-modified messenger RNA (mRNA) encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...
8.
Graziani E, Sung M, Ma D, Narayanan B, Marquette K, Puthenveetil S, et al.
Mol Cancer Ther
. 2020 Aug;
19(10):2068-2078.
PMID: 32747418
The approval of ado-trastuzumab emtansine (T-DM1) in HER2 metastatic breast cancer validated HER2 as a target for HER2-specific antibody-drug conjugates (ADC). Despite its demonstrated clinical efficacy, certain inherent properties within...
9.
Mathur D, Root A, Bugaj-Gaweda B, Bisulco S, Tan X, Fang W, et al.
Clin Cancer Res
. 2020 Jan;
26(9):2188-2202.
PMID: 31996389
Purpose: Gastrointestinal cancers remain areas of high unmet need despite advances in targeted and immunotherapies. Here, we demonstrate potent, tumor-selective efficacy with PF-07062119, a T-cell engaging CD3 bispecific targeting tumors...
10.
Brenneman K, Ramaiah S, Rohde C, Messing D, ONeil S, Gauthier L, et al.
Toxicol Pathol
. 2013 Nov;
42(1):229-42.
PMID: 24226507
Pancreatic toxicity commonly affects the endocrine or exocrine pancreas. However, it can also occur at the endocrine-exocrine interface (EEI), where the capillary network of the islet merges with the capillaries...